LL-37 Peptide Protocol Guide: Dosage, Reconstitution & Immune Support Breakdown
LL-37
LL-37 is an antimicrobial peptide studied for its role in immune defense, wound healing, inflammation control, and microbiome regulation. It is part of the body’s innate immune system and plays a key role in protecting against bacterial, viral, and fungal threats.
How It Works
Antimicrobial Activity ↑ → Immune Modulation ↑ → Tissue Repair ↑ → Inflammation Regulation
LL-37 works by directly disrupting microbial membranes while also signaling immune responses. It plays a dual role in both defending against pathogens and promoting tissue repair.
LL-37 Protocol
5 mg vial + 3.0 mL BAC Water → 1 unit = 16.7 mcg → Gradual Immune + Tissue Support
Standard / Gradual Approach
5 mg vial reconstituted with 3.0 mL bacteriostatic water
1 unit = 16.7 mcg
Days 1–3
Starting Dose
Dose50 mcg
Units3 units
Volume0.03 mL
Days 4–10
Build
Dose100 mcg
Units6 units
Volume0.06 mL
Days 11–21
Higher Range
Dose150 mcg
Units9 units
Volume0.09 mL
Simple structure:
LL-37 can be highly active in immune signaling, so a gradual approach is commonly discussed. Starting low makes it easier to monitor immune response, inflammation shifts, fatigue, and injection tolerance.
LL-37 can be highly active in immune signaling, so a gradual approach is commonly discussed. Starting low makes it easier to monitor immune response, inflammation shifts, fatigue, and injection tolerance.
How to Use LL-37 (Cycle, Timing & Injection)
FrequencyOnce daily
TimingMorning or early day
RouteSubcutaneous, most common
Cycle Length2–4 weeks
Use StyleShort immune-support phase
Best Time to Use
Morning or early day is commonly preferred.
Earlier timing can make it easier to monitor fatigue, immune response shifts, or inflammation changes.
Consistency matters more than exact clock timing.
Where to Inject
Subcutaneous injection is most commonly discussed.
Common sites include abdomen or thigh.
Some use near an affected area in research-based practice.
Rotate injection sites regularly to reduce irritation.
When to Use
During immune-support phases
During skin or wound-healing support phases
During inflammation-regulation phases
During microbiome or antimicrobial-defense research contexts
As a short cycle rather than a long continuous protocol
Simple Strategy
Start Low
LL-37 is highly active in immune signaling, so the goal is usually controlled support rather than aggressive dosing.
Short Phase Use
It is most commonly discussed in short 2–4 week support phases, followed by reassessment.
Real-World vs Clinical Use
Real-World Use
Typical Range50–150 mcg daily
GoalImmune + skin + recovery support
Clinical / Research Context
FocusAntimicrobial + immune signaling
RealityCan be highly dose-sensitive
Reconstitution & Dosing
Reconstitution & Dosing
Vial5 mg
Water3.0 mL
Concentration1.67 mg/mL
Conversion1 unit = 16.7 mcg
Dose Reference
3 units = 50 mcg
6 units = 100 mcg
9 units = 150 mcg
12 units = 200 mcg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down the vial wall
Gently swirl, do not shake
Allow full dissolution
Refrigerate at 2–8°C after mixing
Important:
Unit math depends on vial size and water volume. This example uses a 5 mg vial with 3.0 mL added, creating a 1 unit = 16.7 mcg conversion.
Unit math depends on vial size and water volume. This example uses a 5 mg vial with 3.0 mL added, creating a 1 unit = 16.7 mcg conversion.
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (unmixed)
Refrigerated (2–8°C): ~12–24 months
Frozen (−20°C): up to ~2–3 years
Store sealed, dry, and protected from light
Reconstituted (mixed)
Refrigerated (2–8°C): about 3–4 weeks typical use window
Do not freeze after mixing
Avoid repeated temperature changes
Best Practice
Handling
Keep LL-37 cold, protected from light, and limit unnecessary handling after mixing.
Visual Check
If the solution becomes cloudy, discolored, or contains visible particles, it is safer not to continue using it.
Time Between Cycles
Short Immune Phase → Reassess → Reset → Repeat if Needed
Standard Time Between Cycles
Cycle Length2–4 weeks
Time Off2–4 weeks
Use StyleShort targeted support phase
Why take a break?
LL-37 is highly active in antimicrobial and immune signaling pathways. Taking time off after a short support phase allows immune response, inflammation, and tolerance to be reassessed before repeating.
LL-37 is highly active in antimicrobial and immune signaling pathways. Taking time off after a short support phase allows immune response, inflammation, and tolerance to be reassessed before repeating.
Best Ways to Structure It
Option 12–3 weeks on, 2–4 weeks off
Good for cautious short-cycle use
Option 23–4 weeks on, then reassess
Used when a longer immune or skin-support phase is the goal
Option 3Use only during a targeted support phase
Then stop once the specific recovery or immune-support goal has passed
When to Stop Sooner
Temporary inflammation increase becomes uncomfortable
Fatigue or immune response shifts become noticeable
Injection site irritation becomes persistent
You are continuing without a clear immune or recovery goal
Monitoring During Use
Immune response and symptoms
Skin or wound healing progress
Inflammation levels
Injection site tolerance
Benefits
Supports antimicrobial defense
May aid wound healing
Supports immune modulation
May help regulate inflammation
Potential Side Effects
Injection site irritation
Temporary inflammation increase
Possible fatigue or immune response shifts
Limited long-term human data
Important Notes
LL-37 is highly active in immune signaling
Start low and increase gradually
Short cycles are most commonly discussed
Response varies significantly between individuals
Monitor inflammation, fatigue, and injection tolerance closely during use
Important Disclaimer
LL-37 is an investigational peptide and is not FDA-approved. This content is for educational and research purposes only.
Comments
Post a Comment